Moleculin Biotech Inc (MBRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Moleculin Biotech Inc (MBRX) has a cash flow conversion efficiency ratio of -0.358x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.37 Million) by net assets ($15.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MBRX net asset quality index to measure how much of total assets are equity-financed.
Moleculin Biotech Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Moleculin Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Moleculin Biotech Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Moleculin Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Moleculin Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Solar Alliance Energy Inc
V:SOLR
|
0.001x |
|
MACDONALD MNS EXPL. A
F:3M7
|
N/A |
|
Edible Garden AG Inc
NASDAQ:EDBL
|
0.028x |
|
Miramar Resources Ltd
AU:M2R
|
-0.007x |
|
Fonix Mobile plc
LSE:FNX
|
0.339x |
|
Young & Co.'s Brewery P.L.C
LSE:YNGN
|
0.064x |
|
QcX Gold Corp
V:QCX
|
-0.031x |
|
Vaxtex Cotfab Limited
NSE:VCL
|
-0.091x |
Annual Cash Flow Conversion Efficiency for Moleculin Biotech Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Moleculin Biotech Inc from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see MBRX market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $15.01 Million | $-22.73 Million | -1.515x | +62.04% |
| 2024-12-31 | $5.98 Million | $-23.86 Million | -3.991x | -331.75% |
| 2023-12-31 | $26.07 Million | $-24.10 Million | -0.924x | -74.55% |
| 2022-12-31 | $52.19 Million | $-27.64 Million | -0.530x | -120.74% |
| 2021-12-31 | $78.99 Million | $-18.95 Million | -0.240x | +75.85% |
| 2020-12-31 | $17.89 Million | $-17.77 Million | -0.993x | +10.06% |
| 2019-12-31 | $15.57 Million | $-17.20 Million | -1.104x | -29.18% |
| 2018-12-31 | $14.27 Million | $-12.20 Million | -0.855x | -99.84% |
| 2017-12-31 | $17.12 Million | $-7.32 Million | -0.428x | -70.01% |
| 2016-12-31 | $14.96 Million | $-3.76 Million | -0.252x | -144.25% |
| 2015-12-31 | $-744.70K | $-423.51K | 0.569x | -- |
About Moleculin Biotech Inc
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 po… Read more